ReviewLeukemia2002

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

P La Rosée et al.PubMed ↗Publisher ↗

No numbers read from the abstract.